Sorrento Therapeutics Inc (NASDAQ:SRNE) reported that Dr. Henry Ji, the CEO and Chairman, will share recent company information and developments in a panel discussion in the upcoming “East/West CEO” event in San Francisco, CA, starting from January 6, 2018. During the discussion, he will present the advancement of a proprietary non-viral CAR-T know-how that may fundamentally change the process of CAR constructs integration into T cells.
This unique Sorrento CAR-T technology has by now been used preclinically to generate CD19 CAR-T and CD38 CAR-T cells. These cells have been assessed and matched against CAR-T cells produced using existing retrovirus transduction procedures. Dr. Ji stated that their data indicate that the non-virally produced CAR-T cells fared similarly to retrovirally transduced CAR-T cells with respect to CAR expression, production of cytokine, and cytotoxicity counter to target-expressing tumor cells.
This unique non-viral CAR-T know-how may provide numerous prospective benefits over current virus-based technology utilizing CAR gene-encoding lentivirus, adeno-associated virus or retrovirus to launch CAR constructs into allogeneic or cancer patient T cells.
These prospective benefits of Sorrento’s non-viral CAR-T know-how include site-specific incorporation of CAR constructs into a preselected point in the T cell genome; streamlined process for CAR construct generation without need for time-consuming and laborious CAR-encoding virus generation, validation and release procedures, leading in a shorter advancement timeline for IND preparation; prospective elimination of increased burden to patients of extended monitoring period for the lack of replication competent virus; applicability to both allogeneic and autologous CAR-T treatments; and reduced development timelines to get new CAR-T therapies quicker to patients in need.
Sorrento is intending on applying its unique non-viral CAR-T know-how to CAR-T programs for several solid tumor and hematological indications, counting but not limited to: lymphoma, multiple myeloma, sarcoma, liver cancer, glioma and pancreatic cancer.
In the last trading session, the stock price of Sorrento jumped more than 22% to close the day at $4.65.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: